echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > 2019ASCO concludes: what are the research results of the ten major cancer species this year?

    2019ASCO concludes: what are the research results of the ten major cancer species this year?

    • Last Update: 2019-06-06
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    At the end of the grand meeting, the editor gave you a comprehensive summary of the key points of the progress of the meeting of the top ten cancer species, and showed you the key points of the progress of tumor occurrence ASCO to amg510 "God drug", lung cancer after the line effective rate of 50%! This study included patients with advanced solid tumors treated with krasg12c mutation and treated with amg510 Finally, 29 patients were evaluated, including 10 NSCLC and 19 CRC These patients have been treated with ≥ 2-line therapy in the past The results showed that the overall population's orr (objective effective rate) was 17.24%, and the DCR (disease control rate) was 79.31%, and the effect lasted for a long time The point is that of the 10 NSCLC patients, Orr has reached a new record, reaching 50%, and DCR has a full score of 100%! Amg510 is about to bring salvation to NSCLC patients with KRAS mutation who have no medicine available One NSCLC female, 61 years old, was treated with amg510 (180mg) after receiving radiotherapy, chemotherapy and PD1, reaching PR, lasting for more than 27.4 weeks Another patient received amg510 (360mg) after previous five line treatment failure (including chemotherapy, erlotinib, PD1, dasatinib, m3541), the tumor shrank by 67%, and achieved complete remission of CR at 18 weeks 2 The target drug u3-1402 of HER3 saved the resistance of EGFR, and the control rate was 100%! Different levels of HER3 (ERBB3) expression were found in 57% - 67% of EGFR mutation patients A new drug u3-1402 has been developed Patients with advanced NSCLC with EGFR mutations were treated with u3-1402 in a phase 1 clinical study These patients developed disease after receiving EGFR-TKI (including 1 / 2 generation TKI and oxitinib) The results showed that among the 16 patients who could be evaluated, the tumors of all the patients decreased, with a median reduction of 29% and a DCR of 100%! The key point is that u3-14-2 has curative effect on the secondary activation of different pathways (including c797s, HER2 and CDK4) after EGFR-TKI resistance 3 The highest 5-year survival rate of K drug was 29.6%! Immunotherapy adds another therapeutic effect to lung cancer The 5-year survival rate of patients with lung cancer treated by traditional chemotherapy is between 5% and 10% Take a look at the 5-year OS (total survival) rate of single drug K published by ASCO this year Keynote 001 study showed that the 5-year survival rate of patients with advanced primary lung cancer was 23.2%, and the survival rate of patients with high expression of PDL1 (TPS ≥ 50%) was close to 30% (29.6%)! The 5-year survival rate of 1-49% patients with PDL1 expression was 15.7% The overall 5-year survival rate was 15.5%, PDL1 expression was 25%, PDL1 1% - 49% survival rate was 12.6%, while PDL1 negative (< 1%) was only 3.5% There is no doubt that the efficacy of K drug depends on PDL1, which is a gold index to predict, and the survival time of non beneficiary population is several times shorter 4 Pacific Research: more than half of patients live for 3 years! Good news for late patients! Pacific study analyzed the efficacy of PDL1 mAb I (imfinzi, dewalumab) consolidation therapy for one year after concurrent radiotherapy and chemotherapy in patients with stage III non resectable advanced NSCLC This ASCO conference shows three years of OS (total lifetime) updates The median OS in the durvalumab group was significantly longer than that in the placebo group, which was NR (not achieved) vs 29.1m The 3-year OS rate of the two groups was 57% for drug I vs 43.5% for placebo, which means that more than half of the patients in the advanced stage survived 3 years successfully with drug I, 13.5% more than that with placebo! Compared with the placebo group, the time for patients in drug I group to receive posterior line treatment or death was prolonged, in which the time for the first follow-up treatment doubled (drug I 21.2m vs placebo 10.4m), and the time for the second follow-up treatment was 30.2m vs 17.8m The second-line effective rate of lurbinectdin is 35.2%, creating a new high of small cell efficacy! Lubinectedin (pm1183) was recognized as an orphan drug by FDA last year with beautiful data in phase 1, which was used for second-line treatment of SCLC The follow-up results of this ASCO conference were further released In this study, 105 patients with extensive SCLC who had been treated by first-line chemotherapy were analyzed The results showed that the orr of second-line treatment was 35.2% and the DCR was 68.6%, which was a good effect in the treatment of small cells first In addition, the median dor was 5.3 months In 65% of patients, the tumor volume decreased after using lurbinectdin In terms of survival time, the median OS was 9.3 months, and the one-year OS rate was 34.2% The drug brings new hope for the refractory small cell lung cancer 2 New star rrx-001 reverses platinum resistance The orr of 26.9% rrx-001 is an apparent immunosuppressant that can reverse chemotherapy resistance of small cell lung cancer by regulating the epigenetic characteristics of tumor related macrophages and tumor related neutrophils to affect the tumor microenvironment 26 patients with platinum resistant SCLC were included in this study These patients were treated with rrx-001 once a week and continued to receive EP regimen chemotherapy The use of rrx-001 was discontinued during the course of progression, and the patients were re used with the previously resistant EP regimen (etoposide + cisplatin or carboplatin) on the first day of discontinuation The results showed that after the treatment of rrx-001, the EP was restarted again, 1 patient got CR complete remission, 6 patients got PR partial remission, Orr was 26.9%, median OS was 8.6 months, 12 months OS rate was 44.1%, the effect was amazing Liver cancer 1 K medicine halberd second-line liver cancer, it is thought-provoking! The results of the keynote-240 trial reported at the 2009 ASCO conference showed that the median PFS and OS had no statistically significant benefit compared with placebo in the second-line treatment of liver cancer The median OS of drug K compared with placebo group was 13.9 months vs 10.6 months, P = 0.0238, which did not reach the preset statistical difference There was no significant difference in median PFS between the two groups: 3.0 months vs 2.8 months The effective rate of drug K compared with placebo: 18.3% vs 4.4%, P = 0.00007 The disease control rate was 62.2% vs 53.3% 2 Big surprise! The combination of O + y therapy has been proved to benefit the patients with advanced liver cancer for the first time In the clinical study of orr31% 1 / 2-phase checkmate-040, the first clinical study results of the combination of o-drug (nafulizumab) and CTLA4 inhibitor epimummab (y-drug) for the patients with advanced liver cancer who have been previously treated with sorafenib were published in ASCO 2019 In this study, patients were randomly divided into three groups: 1 mg / kg of [a] O drug + 3 mg / kg of yipi3 q3w or 3 mg / kg of [b] O drug + 1 mg / kg of yipi1 q3w, 240 mg of q2w for each group, or 3 mg / kg of q2w for [C] O drug + 1 mg / kg of Q6W for yipi1 The median OS of group A was the longest, reaching 22.8 months, and the overall survival rate was 44% at 30 months The disease control rate (DCR) of group A, group B and group C were 54%, 43% and 49%, respectively The orr of the total population was 31%, including 5% Cr and 26% pr Objective remission was observed regardless of the level of PD-L1 expression 3 Domestic PD1 combined with FOLFOX4 or GEMOX chemotherapy was the first-line treatment DCR was 79.4% in a two-stage study Patients with advanced HCC (liver cancer) and BTC (cholangiocarcinoma) who had not received systematic treatment were given PD1 carrizumab made in Hengrui (3) Mg / kg, intravenous drip), combined with the classic FOLFOX4 regimen (fluorouracil + calcium folinate + oxaliplatin) or GEMOX regimen (guitar west shore + oxaliplatin) The results showed that in 34 evaluable HCC patients, the confirmed orr was 26.5%, DCR was 79.4%, and the median response time (TTR) was 2.0 months At present, 6 of the 9 patients are still in continuous remission, and the median response duration (mdor) has not yet reached The median PFS was 5.5 months Among 32 evaluable BTC patients, median treatment time was 2.9 months, confirmed orr was 9.4%, and DCR was as high as 90.6% The median TTR was 1.9 months and mdor was 5.3 months The median PFS has not been reached However, the median overall survival time (OS) of HCC and BTC patients has not been achieved Digestive tract tumor (stomach / esophagus / colorectal / pancreas) 1 New breakthrough! In this study, 50 patients with advanced gastric cancer or colorectal cancer were included The number of previous median treatment lines was 3 lines After entering the group, they received the treatment of regofinib + nafumab It was found that 19 patients had pr, 1 patient had Cr, the overall orr was 40%, and the DCR was 88% The median treatment duration was 6.1 months The orr was 36% in colorectal cancer group and 33% in MSS patients So the patients with gastric cancer were MSS and orr was 44% The median PFS was 6.3 months for colorectal cancer and 5.8 months for gastric cancer 2 Carrizumab combined with apatinib and chemotherapy in the first-line treatment of advanced esophageal squamous cell carcinoma Poster published a phase II study on the first-line treatment of advanced esophageal squamous cell carcinoma (ESCC) on 80% 2019asco In this study, 29 patients (the latest data added by Professor Huang Jing should be 30) with advanced ESCC were treated with carrizumab combined with apatinib and chemotherapy (paclitaxel liposome + nedaplatin) Then maintenance therapy was performed with carrizumab, apatinib or both At present, the total Orr and DCR of 30 patients in the group are as high as 80% and 96.7% respectively The data of PFS and OS are not mature, but the long-term results are also expected from the good benefits shown by the recent results 3 Three drugs joint innovation record, colorectal cancer new program coming! This ASCO shows the data of the phase III beacon study The study head-to-head compared the efficacy of the BRAF inhibitor encorafenib + MEK inhibitor bimetinib + cetuximab compared with FOLFIRI + cetuximab in the treatment of BRAF mutant colorectal cancer patients! These patients had previously failed in one or two treatment regimens The results show that the effective rate of the combination of three drugs is as high as 44%! Reach the highest in the history of colon cancer BRAF! 4 Car-t challenges solid tumor! The effective rate of treatment for gastric cancer and pancreatic cancer is 33% One clinical data of car-t treatment for solid tumors of gastric and pancreatic cancer is published in the conference The researchers found that claudin-18 was highly expressed in gastric cancer and pancreatic cancer, so they developed car-t therapy (car-cldn18.2) targeting claudin-18 A total of 12 patients with claudin-18-positive multidrug-resistant gastric cancer and pancreatic cancer were included The patients in the group received car-t cell therapy for 1-5 cycles The final 11 patients could evaluate the efficacy, 1 Cr, 3 pr (2 gastric cancer, 1 pancreatic cancer), 5 stable, and 2 progress The overall orr was 33.3%, DCR was 75%, and median PFS was 130 days 5 The data of gastric cancer with k-drug is hit hard: single drug is not better than chemotherapy! K drug combination chemotherapy OS is not better than chemotherapy! Keynote 062, which was released at the meeting, is a three-stage large-scale study of k-drug ± chemotherapy vs first-line chemotherapy for gastric cancer The results showed that for patients with positive PDL1 (CPS ≥ 1), there was no difference in median OS between the k-drug group and the chemotherapy group, 10.6m vs 11.1m When the analysis population was raised to CPS ≥ 10, drug K finally showed an advantage, with a median OS of 17.4M vs 10.8m The most regrettable thing is that the K + chemotherapy combined treatment group failed to show the benefit (12.3m vs 10.8m) in the population with CPS ≥ 10, and the immune + chemotherapy was not superior to the chemotherapy 1 + 1 = 1 The loss of gastric cancer was startling 6 The PFS of the first line maintenance therapy with olaparide for gbrca + pancreatic cancer doubled! In the phase III Polo study, 154 patients with gbrca + metastatic pancreatic cancer who had not progressed after first-line platinum chemotherapy were evaluated for the efficacy of olaparide 300mg twice daily single drug use as first-line maintenance therapy The results showed that olapalin significantly prolonged median PFS (7.4 vs 3.8 months) and reduced the risk of disease progression and death by 47% (HR 0.53) compared with placebo, and the 1-year progression free survival rate was significantly higher in the placebo group (34% vs 1
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.